Best European Stock Screener in 2026: 6 Tools Compared

The best European stock screener in 2026 is ScreenerHero — it covers US, Canadian, and all European exchanges including microcaps on alternative markets (Euronext Growth, First North, EGM), with a free tier that requires no account, and fundamental filters — P/E, ROE, EV/EBITDA, margins, dividend yield — that work reliably for European small caps. At €29/month Pro, it is less expensive than every dedicated European competitor.

Last updated: July 2026.

What makes a European stock screener good?

A European stock screener is a tool that lets investors filter stocks listed on European exchanges by fundamental and technical criteria. Not all screeners marketed as "global" cover European markets well — many list European companies but lack reliable fundamental data for small and mid-cap names.

To be genuinely useful for European equity investors, a screener needs to:

1. Cover the major European exchanges — XETRA (Germany), Euronext Paris (France), BME (Spain), Borsa Italiana (Italy), Euronext Amsterdam (Netherlands), Euronext Brussels (Belgium), Euronext Lisbon (Portugal), and the Nordic exchanges.
2. Include alternative markets — Euronext Growth, Nasdaq First North, EGM Milan, GPW NewConnect. This is where most European microcaps trade.
3. Have reliable fundamental data below large cap — P/E, P/B, ROE, EV/EBITDA, profit margin. For companies below €500M market cap, many screeners show stale or missing data.
4. Update at least daily — end-of-day (EOD) data is acceptable for fundamental screeners. Real-time is not necessary for most investment strategies.
5. Be fast enough to iterate — filter results should update in under two seconds across a universe of thousands of names.

The 6 main European stock screeners compared

1. ScreenerHero — Best overall for European fundamental screening

Coverage: US (NYSE, NASDAQ), Canada (TSX, TSXV), all major European exchanges including Euronext Growth, First North (Stockholm, Copenhagen, Helsinki), EGM Milan, and GPW NewConnect.

Filters: P/E, P/B, ROE, EV/EBITDA, profit margin, revenue growth, dividend yield, beta, market cap. All filters work reliably for European stocks down to microcap level.

Free tier: Full screener, no account required. No time limit.

Paid plan: €29/month Pro. Annual plans available.

Best for: Investors who screen US, Canadian, and European stocks in a single tool. Particularly well-suited for European microcap screening where most other tools have data gaps.

Limitations: No options data, no earnings transcripts, no news integration. Basic price charts — not a charting platform.

2. TradingView — Best for chart-driven investors with European coverage

Coverage: Global including all major European exchanges. Data quality degrades below €500M market cap for alternative market listings (Euronext Growth, First North, EGM).

Filters: Technical-first — RSI, moving averages, chart patterns. Fundamental filters available but inconsistent for European small caps on free plan.

Free tier: Account required. Screener restricted on free plan.

Paid plan: $15–60/month depending on tier.

Best for: Technical analysts whose workflow is chart-driven. European coverage for large and mid caps is good; microcap fundamental data has gaps.

Limitations: Fundamental data for European small caps is inconsistent. Screener is secondary to charting — not built for systematic fundamental screening.

3. Stockopedia — Best for score-driven European equity research

Coverage: UK-weighted, plus continental Europe. No Canadian coverage. European microcap coverage has gaps, particularly outside the UK.

Filters: StockRanks composite scores (Quality, Value, Momentum combined) plus custom filters. The composite approach suits investors who want pre-computed signals rather than raw metric sliders.

Free tier: No free tier. Trial available.

Paid plan: €60/month (Europe only) · €80/month (Europe + US). The most expensive option in this comparison.

Best for: UK and European investors who want a well-designed composite scoring system. StockRanks is a genuinely thoughtful approach to quality + value + momentum.

Limitations: €80/month for US + Europe is 2.7× ScreenerHero's price. No Canadian coverage. UX is dated. UK-weighted — continental European microcap coverage is inconsistent.

4. MarketScreener — Broadest European fundamental database

Coverage: Broad European coverage, including smaller continental exchanges. Strong on analyst estimates and consensus data.

Filters: 300–600 fundamental filters. One of the most comprehensive European fundamental databases available to retail investors.

Free tier: Basic access. Full features require paid subscription.

Paid plan: ~€30–34/month.

Best for: Investors who need analyst consensus estimates and news alongside screening. Well-suited for monitoring European coverage breadth.

Limitations: The screener UX requires page reloads for each filter change — slow compared to modern screeners. Product is built around editorial content (news, analyst reports) with the screener as a secondary feature. Not decision-oriented.

5. TIKR — Best for historical financial data depth

Coverage: 100,000+ stocks across 92 countries including Europe. Fundamental data quality for European companies below €500M market cap is inconsistent — names are listed but filter results are often incomplete.

Filters: Extensive fundamental filters. Historical data goes back 20 years on Pro — deeper historical context than most competitors.

Free tier: Freemium with deliberate friction. Account required.

Paid plan: $10–15/month Plus · $40–55/month Pro.

Best for: Investors who need 20-year historical financials and earnings transcripts for individual company research. Good for deep-dive research on large and mid-cap names globally.

Limitations: European microcap data is thin. UI is less dense than ScreenerHero or Finviz — not optimised for rapid filter iteration. Euronext Growth, First North, and EGM names are often listed without usable fundamental data.

6. Finviz — Best for US equities only

Coverage: US stocks only (NYSE, NASDAQ, NYSE American, OTC). A small number of European ADRs — no meaningful European exchange coverage.

Filters: Excellent — the deepest US fundamental screener available. 60+ fundamental and technical filters, insider data, institutional ownership.

Free tier: Ad-supported, delayed data. No account required.

Paid plan: $39.50/month Elite · $299.50/year ($24.96/month).

Best for: US equity investors. Finviz is the industry benchmark for US stock screening — nothing surpasses it for US-only workflows.

Limitations: No European coverage. No Canadian coverage. The dominant choice for US stocks, irrelevant for European ones.

European stock screener comparison table (2026)

Data as of June 2026.

Which European stock screener should you use?

If you screen European stocks by fundamental criteria (P/E, ROE, EV/EBITDA, margins) as your primary workflow: → ScreenerHero. Built specifically for this, free to start, covers microcaps that other tools miss.

If charts drive your workflow and European coverage is secondary: → TradingView. No screener beats it for charting. European fundamental data for large caps is good; microcap coverage is inconsistent.

If you want composite scores (Quality + Value + Momentum combined) rather than raw filters: → Stockopedia. StockRanks is a thoughtful system — but €60–80/month is significant, and US coverage requires the more expensive plan.

If you need analyst consensus estimates and news alongside screening: → MarketScreener. Broadest EU fundamental database, best-in-class for consensus data. Slow UX.

If you need 20-year historical financials and earnings transcripts: → TIKR Pro. Historical depth is a genuine advantage for long-term investors. Accept the European microcap data gaps.

If you only screen US stocks: → Finviz. Not relevant for European screening — but the best US screener available.

Why most US-centric screeners fail for European stocks

European equity markets are not a single market. They are a patchwork of 14+ major exchanges — each with different listing standards, currency exposure, liquidity profiles, and regulatory frameworks. A screener built for the S&P 500 universe fails for European equities for four structural reasons:

1. Data sourcing complexity. A single US data provider covers the NYSE and NASDAQ. European data requires relationships with 14+ exchanges, each with different data formats, reporting languages, and update frequencies. Most US-facing tools use one or two European data sources that cover large caps adequately and small caps poorly.

2. Microcap exclusion. Many US screeners exclude stocks below $100M or $500M market cap. In Europe, a €100M company can be a high-quality industrial business with 15% EBIT margins and no debt — just small by US standards. Excluding microcaps eliminates a large portion of the European opportunity set.

3. Alternative market gaps. Euronext Growth Paris, Nasdaq First North, EGM Milan, and GPW NewConnect are the European equivalent of the US OTC markets — they list hundreds of smaller companies that trade outside the main market. Most global screeners either omit these markets entirely or list names without usable fundamental data.

4. Currency inconsistency. European stocks trade in EUR, GBP, SEK, NOK, DKK, CHF, PLN, and other currencies. Screeners that convert everything to USD at a single point in time produce inconsistent cross-country comparisons. A good European screener handles multi-currency natively.

How to screen European stocks effectively

A practical starting point for a quality European equity screen:

Step 1 — Define your universe. Choose exchanges that match your strategy. For pan-European coverage: XETRA, Euronext Paris, BME, Borsa Italiana, Euronext Amsterdam. Add First North exchanges for Nordic exposure. Add Euronext Growth for smaller French companies.

Step 2 — Set a market cap floor. €100M is a reasonable minimum for most strategies — it excludes the least liquid names while keeping most genuine micro and small-cap opportunities in scope.

Step 3 — Screen for profitability. Positive operating margin eliminates most speculative and pre-revenue names. Set: operating margin > 0%.

Step 4 — Add a valuation filter. P/E below 20 and EV/EBITDA below 12 are reasonable starting points for a broad European quality-at-discount screen. Adjust by sector — utilities and financials trade on different multiples.

Step 5 — Sort and review. Sort results by EV/EBITDA ascending to surface the cheapest names meeting your criteria. Review the top 20–30. Expect 15–30% to have data issues (stale reporting dates, unusual corporate structures, one-off items distorting ratios).

A full pan-European screen on these criteria typically returns 100–200 companies — a manageable starting list for further fundamental research.

Frequently asked questions

What is the best free European stock screener?

ScreenerHero is the best free European stock screener in 2026. The full screener — including P/E, ROE, EV/EBITDA, and margin filters across all European exchanges — is accessible without creating an account. TradingView also has a free tier but requires account creation and restricts filter combinations on the free plan.

Does Finviz cover European stocks?

No. Finviz covers US equities (NYSE, NASDAQ, OTC) and a small number of European ADRs listed in the US. It does not cover XETRA, Euronext, BME, Borsa Italiana, or any European exchange directly. Finviz is the best screener for US stocks — for European stocks, it is not a relevant option.

What is the best screener for European microcaps?

ScreenerHero covers European microcaps on alternative markets — Euronext Growth Paris, Nasdaq First North (Stockholm, Copenhagen, Helsinki), EGM Milan, and GPW NewConnect — with reliable fundamental data. Most other screeners list these companies but lack usable P/E, ROE, and EV/EBITDA data for the majority of names.

Is TradingView good for European stocks?

TradingView covers European large and mid-cap stocks well and has good price data across all major exchanges. For fundamental screening of European small caps — particularly on alternative markets — the data quality is inconsistent. TradingView is better for chart-driven workflows than for systematic fundamental screening of European equities.

How much does a European stock screener cost?

• ScreenerHero: Free (core features) · €29/month Pro
• TradingView: Free (limited) · $15–60/month
• Stockopedia: €60–80/month
• MarketScreener: ~€30–34/month
• TIKR: $15–55/month

The most expensive options (Stockopedia at €80/month for US + Europe) do not necessarily offer better European fundamental screening than ScreenerHero at €29/month — they offer different workflows (composite scores, analyst estimates) rather than better raw filter coverage.

Can I screen European stocks for free without creating an account?

Yes — ScreenerHero's full fundamental screener works without account creation. TradingView requires an account even for its free tier. MarketScreener offers some free access without an account. Stockopedia and TIKR require account creation.

Related guides

• Finviz Alternative for European Stocks — full comparison of Finviz vs. European screeners, with a feature table
• European Dividend Stocks: How to Find High-Yield Opportunities — dividend-specific screening guide with sector analysis and withholding tax table
• How to Screen European Stocks — step-by-step screening workflow for European equities
• European Microcap Investing Guide — how to find and screen European microcaps on alternative markets
• Value Investing in Europe 2026 — value-focused screening approach for European equities

Open the European stock screener → — free, no account required. Covers XETRA, Euronext Paris, BME, Borsa Italiana, Euronext Growth, First North, EGM, NewConnect, and more. Pro at €29/month.